<DOC>
	<DOC>NCT01515007</DOC>
	<brief_summary>The DRCFI treatment will influence the time to first pulmonary exacerbation compared to placebo.</brief_summary>
	<brief_title>Phase 3 Study With Dual Release Ciprofloxacin for Inhalation in Non-CF Bronchiectasis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Verified bronchiectasis diagnosis Pseudomonas aeruginosa lung infection Cystic Fibrosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Bronchiectasis, non-CF, Ciprofloxacin, Liposome</keyword>
</DOC>